You are here: Home: Audio Program Guide: BCU 3 | 2007 Audio: BCU 3 | 2007
 
  Go to interview with Eric P Winer, MD
Go to interview with Aman U Buzdar, MD
Go to Tumor Panel Case Discussion
Go to interview with Anthony Howell, MD
Go to interview with Soonmyung Paik, MD
 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Holmes, MD Interview with Eric P Winer, MD
Director, Breast Oncology Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts


  
  Click here to download the entire interview  
Track 1 Second interim analysis of BCIRG 006 adjuvant trastuzumab (H) trial: AC docetaxel (ACarrowT) versus
ACarrowTH versus docetaxel, carboplatin and trastuzumab (TCH)
Track 2 TOPO II in treatment decision-making for patients with HER2-positive breast cancer
Track 3 Treatment options for patients with HER2- positive breast cancer
Track 4 BIG 2-06: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study
Track 5 Lapatinib-associated cardiac toxicity
Track 6 Lapatinib for the treatment of HER2-positive metastatic CNS disease

Track 7 Recurrence of CNS disease in patients with HER2-positive disease
Track 8 Clinical approach to small, node-negative, HER2- positive tumors
Track 9 Adjuvant chemotherapy for HER2-positive or hormone receptor-positive disease
Track 10 Incorporation of bevacizumab into adjuvant clinical trials
Track 11 Role of bevacizumab for patients with triple-negative disease
Track 12 Clinical trial strategies for patients with residual disease after neoadjuvant therapy
Track 13 Use of capecitabine combined with bevacizumab as first-line therapy
Track 14 Evaluation of agents in the trastuzumab-refractory setting
Track 15 Continuation of bevacizumab at disease progression
Track 16 Clinical management of HER2-positive, metastatic disease
     
Mamounas, MD Aman U Buzdar, MD
Professor of Medicine
Deputy Chairman
Department of Breast Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

  
  Click here to download the entire interview  
Track 1 Delayed adjuvant endocrine therapy
Track 2 Endocrine therapy versus chemotherapy for hormone receptor-positive, metastatic disease
Track 3 Sequencing hormonal therapy in postmenopausal patients with metastatic disease
Track 4 EFECT trial: Fulvestrant versus exemestane following prior nonsteroidal aromatase inhibitor (AI) therapy
Track 5 Use of a fulvestrant loading dose
Track 6 Therapeutic strategy combining fulvestrant with an AI

Track 7 Hormonal therapy for premenopausal patients with metastatic disease
Track 8 Unresolved issues in adjuvant endocrine therapy
Track 9 Cross talk between HER2 and ER pathways: Implications for treatment
Track 10 Lapatinib and paclitaxel in patients with newly diagnosed inflammatory breast cancer
Track 11 Pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy
Track 12 Capecitabine with or without lapatinib for HER2- positive metastatic disease
Track 13 Oxford Overview: ATLAS/aTTom and benefit from extended adjuvant tamoxifen
arrow
Track 14 Oxford Overview: Survival benefit with adjuvant AIs
arrow
Track 15 Oxford Overview: Hormone receptor status and benefit of chemotherapy
arrow
Track 16 Use of the Oncotype DX™ assay to identify patients with hormone receptor-positive disease who may benefit from chemotherapy
arrow
Track 17 BCIRG 006: Second interim analysis of adjuvant ACTH versus TCH in HER2-positive disease
arrow
Track 18 TOPO II as a predictor of benefit from anthracycline-containing chemotherapy
     
Tumor Panel Case Discussion:
Leyland, MD Brian Leyland-Jones, MD, PhD
VP Health Affairs and Director
Winship Cancer Institute
Emory University
School of Medicine
Atlanta, Georgia		 Pegram, MD Mark D Pegram, MD
Associate Professor of Medicine
David Geffen School of Medicine
at UCLA; Director, Women’s
Cancer Program, UCLA/Jonsson
Comprehensive Cancer Center
Los Angeles, California
 
  Click here to download the entire case discussion  
Track 1 Case discussion: A 34-year-old woman with a 0.5-cm, high-grade, ER-positive, PR-positive, HER2-amplified, node-negative tumor
Track 2 Estimating prognosis and benefit from therapy for patients with small, HER2-positive tumors
Track 3 Treatment of smaller, ER-positive, PR-positive, HER2-positive, node-negative breast cancer
Track 4 Clinical implications of BCIRG 006 in selection of adjuvant therapy
Track 5 Case discussion: A 53-year-old woman with a T1, ER-positive, PR-negative, HER2-amplified, Grade III, node-negative tumor
Track 6 Degree of HER2 amplification and responsiveness to trastuzumab

Track 7 Ovarian suppression/AI with trastuzumab for premenopausal patients with hormone receptor-positive, HER2-positive disease
Track 8 Trastuzumab monotherapy for lower-risk, HER2-positive disease
Track 9 Duration of adjuvant trastuzumab
Track 10 Case discussion: A 60-year-old woman with a five-centimeter, ER-positive, PR-positive, HER2- amplified, node-positive, inflammatory breast cancer with multiple comorbidities
Track 11 Adjuvant chemotherapy/trastuzumab in patients with very high-risk breast cancer and cardiac disease
Track 12 Case discussion: A 49-year-old premenopausal woman with a nine-centimeter, ER-negative, PR-negative, HER2-amplified, invasive tumor
Track 13 Neoadjuvant chemotherapy/trastuzumab for locally advanced, HER2-positive disease
Track 14 Treatment of residual disease after induction therapy and surgery
Track 15 Case discussion: A 31-year-old woman with Grade III, ER-negative, PR-negative, HER2- positive inflammatory breast cancer and diffuse bone and visceral metastases
Track 16 Selection of therapy for a patient with HER2-positive inflammatory breast cancer and de novo metastatic disease
Track 17 Treatment after progression on first-line chemotherapy/trastuzumab
Track 18 Combination therapy with trastuzumab and lapatinib
Track 19 BIG 2-06: ALTTO adjuvant trial of trastuzumab, lapatinib or the combination
Track 20 Potential CNS-protective effect of lapatinib in HER2-positive disease
Track 21 Lapatinib and cardiotoxicity
Track 22 Case discussion: A 67-year-old woman with asymptomatic lung and liver metastases who was previously treated with ACarrowdocetaxel for ER-negative, PR-negative, HER2-amplified breast cancer
Track 23 Treatment of trastuzumab-naïve metastatic disease after treatment with adjuvant ACarrowdocetaxel
     
Lipton, MD Anthony Howell, MD
Professor of Medical Oncology
Christie Hospital NHS Trust
University of Manchester
Manchester, England

  
  Click here to download the entire interview  
Track 1 Analysis of fracture risk factors from the ATAC trial: Five-year data
Track 2 Delayed adjuvant AI therapy
Track 3 Clinical trials evaluating fulvestrant alone or combined with AIs in the metastatic setting
Track 4 Mechanisms of action: Rationale for combination therapy with fulvestrant and an AI
Track 5 Treatment of premenopausal women with hormone receptor-positive disease
Track 6 TAnDEM: Anastrozole with or without trastuzumab in patients with HER2-positive, metastatic disease

Track 7 Long-term effects of tamoxifen in the preventive setting
Track 8 IBIS-2 and MA3 trials evaluating AIs for chemoprevention
Track 9 STAR trial: Raloxifene versus tamoxifen for postmenopausal women at high risk
Track 10 Intermittent versus continuous calorie restriction in postmenopausal women with breast cancer
Track 11 WINS: Dietary fat reduction and breast cancer outcome
Track 12 Women’s Health Initiative, hormone replacement therapy and risk of breast cancer

     
Paik, MD Soonmyung Paik, MD
Director, Division of Pathology
National Surgical Adjuvant Breast and Bowel Project
Pittsburgh, Pennsylvania
  
  Click here to download the entire interview  
Track 1 Identification of predictive markers for adjuvant trastuzumab
Track 2 ASCO/College of American Pathologists recommendations for quality control of HER2 assessment
Track 3 Quality control in the assessment of hormone receptor status
Track 4 Quantitative analysis of ER and PR by Oncotype DX association with prognosis and prediction of tamoxifen benefit
Track 5 Background for the evaluation of HER2 and cMYC coamplification
Track 6 Impact of HER2 and cMYC coamplification on benefit from trastuzumab

Track 7 Utility of the Oncotype DX assay for patients with HER2-positive and node-positive disease
Track 8 Development of a tumor gene assay for recurrence risk in colon cancer
Track 9 Evaluation of the Oncotype DX assay in the TAILORx trial
Track 10 Quantitative analysis of ER and HER2 via RNA methodologies
Track 11 NSABP-B-40 correlative tissue studies: Predictors of pathologic complete response
Track 12 Impact of chemotherapy on hormone receptor-positive disease